Details on high frequency blood collection, data analysis, available material and patient characteristics in BIOMArCS

• Published in: Data in brief 2019-12, Vol.27, p.104750-104750, Article 104750
• Main Authors: Boersma, Eric, Vroegindewey, Maxime M., van den Berg, Victor J., Asselbergs, Folkert W., van der Harst, Pim, Kietselaer, Bas, Lenderink, Timo, Oude Ophuis, Anton J., Umans, Victor A.W.M., de Winter, Robbert J., Oemrawsingh, Rohit M., Akkerhuis, K. Martijn
• Format: Article
• Language: English
• Subjects: Acute coronary syndrome; Biomarkers; Medicine and Dentistry; Repeated blood sampling
• ISSN: 2352-3409; 2352-3409
• DOI: 10.1016/j.dib.2019.104750

The Biomarker Study to Identify the Acute Risk of a Coronary Syndrome (BIOMArCS) is a prospective, observational study that has been designed to study the evolution of blood biomarkers in post-acute coronary syndrome (ACS) patients. In our recently published study “Temporal evolution of Myeloperoxidase and Galectin 3 during 1 year after acute coronary syndrome admission” [1] in the American Heart Journal, we demonstrated that repeatedly measuring MPO and Galectin-3 does not aid to differentiate between patients with and without adverse cardiac events during 1-year follow-up. In this Data-In-Brief article, we present further details on data collections and data analysis. In addition, a detailed description of baseline characteristics and the distribution of blood sampling moments is provided. The BIOMArCS dataset contains clinical information and follow-up data on all enrolled 844 patients. These patients underwent a median of 17 (25th −75th percentile 12–20) repeated blood samples in the first year after the index ACS. Blood samples were stored at −80 °C within a median of 82 (25th-75th percentile 58–117) minutes after withdrawal. We collected whole blood, citrate plasma, EDTA plasma, serum and DNA. The dataset used for the analysis in the accompanying research paper has been made available online. We welcome collaborations for further use of our data, whether or not in combination with other biobanks.